;PMID: 10485468
;source_file_1213.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..129] = [t:42..129]
;2)section:[e:133..230] = [t:133..230]
;3)section:[e:234..340] = [t:234..340]
;4)sentence:[e:344..542] = [t:344..542]
;5)sentence:[e:543..745] = [t:543..745]
;6)sentence:[e:746..877] = [t:746..877]
;7)sentence:[e:878..1068] = [t:878..1068]
;8)sentence:[e:1069..1351] = [t:1069..1351]
;9)sentence:[e:1352..1556] = [t:1352..1556]
;10)section:[e:1560..1605] = [t:1560..1605]

;section 0 Span:0..37
;Cancer Res  1999 Sep 1;59(17):4257-60
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1999)
        (NNP:[17..20] Sep) (CD:[21..26] 1;59-LRB-) (CD:[26..28] 17)
        (-RRB-:[28..29] -RRB-) (CD:[29..34] :4257) (NN:[34..35] -)
        (CD:[35..37] 60)))

;sentence 1 Span:42..129
;Frequent somatic mutations of the beta-catenin gene in intestinal-type
;gastric  cancer.
;[76..88]:gene-rna:"beta-catenin"
;[97..128]:malignancy:"intestinal-type gastric  cancer"
(SENT
  (NP-HLN
    (NP (JJ:[42..50] Frequent) (JJ:[51..58] somatic) (NNS:[59..68] mutations))
    (PP (IN:[69..71] of)
      (NP (DT:[72..75] the) (NN:[76..88] beta-catenin) (NN:[89..93] gene)))
    (PP (IN:[94..96] in)
      (NP
        (NML (JJ:[97..107] intestinal) (HYPH:[107..108] -) (NN:[108..112] type))
        (JJ:[113..120] gastric) (NN:[122..128] cancer)))
    (.:[128..129] .)))

;section 2 Span:133..230
;Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh
;ST,  Yoo NJ, Lee JY.
(SEC
  (FRAG (NNP:[133..137] Park) (NNP:[138..140] WS) (,:[140..141] ,)
        (NNP:[142..144] Oh) (NNP:[145..147] RR) (,:[147..148] ,)
        (NNP:[149..153] Park) (NNP:[154..156] JY) (NNP:[156..157] ,)
        (NNP:[158..161] Lee) (NNP:[162..164] SH) (,:[164..165] ,)
        (NNP:[166..170] Shin) (NNP:[171..173] MS) (,:[173..174] ,)
        (NNP:[175..178] Kim) (NNP:[179..181] YS) (,:[181..182] ,)
        (NNP:[183..186] Kim) (NNP:[187..189] SY) (,:[189..190] ,)
        (NNP:[191..194] Lee) (NNP:[195..197] HK) (,:[197..198] ,)
        (NNP:[199..202] Kim) (NNP:[203..205] PJ) (,:[205..206] ,)
        (NNP:[207..209] Oh) (NNP:[210..212] ST) (,:[212..213] ,)
        (NNP:[215..218] Yoo) (NNP:[219..221] NJ) (,:[221..222] ,)
        (NNP:[223..226] Lee) (NNP:[227..229] JY) (.:[229..230] .)))

;section 3 Span:234..340
;Department of Pathology and Cancer Research Institute, Catholic University 
;Medical College, Seoul, Korea.
(SEC
  (FRAG (NNP:[234..244] Department) (IN:[245..247] of)
        (NNP:[248..257] Pathology) (CC:[258..261] and) (NNP:[262..268] Cancer)
        (NNP:[269..277] Research) (NNP:[278..287] Institute) (IN:[287..288] ,)
        (NNP:[289..297] Catholic) (NNP:[298..308] University)
        (NNP:[310..317] Medical) (NNP:[318..325] College) (,:[325..326] ,)
        (NNP:[327..332] Seoul) (,:[332..333] ,) (NNP:[334..339] Korea)
        (.:[339..340] .)))

;sentence 4 Span:344..542
;The increased level of cytoplasmic beta-catenin through the mutations to
;either  beta-catenin or adenomatous polyposis coli (APC) has been proposed as
;an  important oncogenic step in various tumors.
;[379..391]:gene-generic:"beta-catenin"
;[425..437]:gene-rna:"beta-catenin"
;[441..467]:gene-rna:"adenomatous polyposis coli"
;[469..472]:gene-rna:"APC"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[344..347] The) (VBN:[348..357] increased) (NN:[358..363] level))
      (PP (IN:[364..366] of)
        (NP (JJ:[367..378] cytoplasmic) (NN:[379..391] beta-catenin)))
      (PP (IN:[392..399] through)
        (NP
          (NP (DT:[400..403] the) (NNS:[404..413] mutations))
          (PP (TO:[414..416] to)
            (NP (CC:[417..423] either)
              (NP (NN:[425..437] beta-catenin))
              (CC:[438..440] or)
              (NP
                (NP (JJ:[441..452] adenomatous) (NN:[453..462] polyposis)
                    (NN:[463..467] coli))
                (NP (-LRB-:[468..469] -LRB-) (NN:[469..472] APC)
                    (-RRB-:[472..473] -RRB-))))))))
    (VP (VBZ:[474..477] has)
      (VP (VBN:[478..482] been)
        (VP (VBN:[483..491] proposed)
          (NP-1 (-NONE-:[491..491] *))
          (PP (IN:[492..494] as)
            (NP
              (NP (DT:[495..497] an) (JJ:[499..508] important)
                  (JJ:[509..518] oncogenic) (NN:[519..523] step))
              (PP (IN:[524..526] in)
                (NP (JJ:[527..534] various) (NNS:[535..541] tumors))))))))
    (.:[541..542] .)))

;sentence 5 Span:543..745
;Gastric cancer showed frequent  genetic alterations of the APC gene, and the
;risk for gastric cancer in familial  adenomatosus polyposis patients is 10
;times higher than that in the general  population.
;[543..557]:malignancy:"Gastric cancer"
;[602..605]:gene-rna:"APC"
;[629..643]:malignancy:"gastric cancer"
;[647..679]:malignancy:"familial  adenomatosus polyposis"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[543..550] Gastric) (NN:[551..557] cancer))
      (VP (VBD:[558..564] showed)
        (NP
          (NP (JJ:[565..573] frequent) (JJ:[575..582] genetic)
              (NNS:[583..594] alterations))
          (PP (IN:[595..597] of)
            (NP (DT:[598..601] the) (NN:[602..605] APC) (NN:[606..610] gene))))))
    (,:[610..611] ,) (CC:[612..615] and)
    (S
      (NP-SBJ
        (NP (DT:[616..619] the) (NN:[620..624] risk))
        (PP (IN:[625..628] for)
          (NP (JJ:[629..636] gastric) (NN:[637..643] cancer)))
        (PP (IN:[644..646] in)
          (NP
             (JJ:[647..655] familial) (JJ:[657..669] adenomatosus)
             (NN:[670..679] polyposis)
            (NNS:[680..688] patients))))
      (VP (VBZ:[689..691] is)
        (ADJP-PRD
          (ADJP
            (NP (CD:[692..694] 10) (NNS:[695..700] times))
            (JJR:[701..707] higher))
          (PP (IN:[708..712] than)
            (NP
              (NP (DT:[713..717] that))
              (PP (IN:[718..720] in)
                (NP (DT:[721..724] the) (JJ:[725..732] general)
                    (NN:[734..744] population))))))))
    (.:[744..745] .)))

;sentence 6 Span:746..877
;These findings raise the possibility that mutations of beta-catenin  may also
;be associated with the development of gastric cancer.
;[801..813]:gene-rna:"beta-catenin"
;[862..876]:malignancy:"gastric cancer"
(SENT
  (S
    (NP-SBJ (DT:[746..751] These) (NNS:[752..760] findings))
    (VP (VBP:[761..766] raise)
      (NP
        (NP (DT:[767..770] the) (NN:[771..782] possibility))
        (SBAR (IN:[783..787] that)
          (S
            (NP-SBJ-1
              (NP (NNS:[788..797] mutations))
              (PP (IN:[798..800] of)
                (NP (NN:[801..813] beta-catenin))))
            (VP (MD:[815..818] may)
              (ADVP (RB:[819..823] also))
              (VP (VB:[824..826] be)
                (VP (VBN:[827..837] associated)
                  (NP-1 (-NONE-:[837..837] *))
                  (PP-CLR (IN:[838..842] with)
                    (NP
                      (NP (DT:[843..846] the) (NN:[847..858] development))
                      (PP (IN:[859..861] of)
                        (NP (JJ:[862..869] gastric) (NN:[870..876] cancer))))))))))))
    (.:[876..877] .)))

;sentence 7 Span:878..1068
;We detected seven  somatic mutations in a portion of exon 3 encoding for the
;glycogen synthase  kinase 3beta phosphorylation consensus region of the
;beta-catenin gene in 43  gastric cancers.
;[905..914]:variation-event:"mutations"
;[931..937]:variation-location:"exon 3"
;[955..986]:gene-protein:"glycogen synthase  kinase 3beta"
;[1027..1039]:gene-rna:"beta-catenin"
;[1052..1067]:malignancy:"gastric cancers"
(SENT
  (S
    (NP-SBJ (PRP:[878..880] We))
    (VP (VBD:[881..889] detected)
      (NP
        (NP (CD:[890..895] seven) (JJ:[897..904] somatic)
            (NNS:[905..914] mutations))
        (PP (IN:[915..917] in)
          (NP
            (NP (DT:[918..919] a) (NN:[920..927] portion))
            (PP (IN:[928..930] of)
              (NP
                (NP (NN:[931..935] exon) (CD:[936..937] 3))
                (VP (VBG:[938..946] encoding)
                  (PP-CLR (IN:[947..950] for)
                    (NP
                      (NP (DT:[951..954] the)
                        (NML (NN:[955..963] glycogen) (NN:[964..972] synthase)
                             (NN:[974..980] kinase) (NN:[981..986] 3beta))
                        (NN:[987..1002] phosphorylation)
                         (NN:[1003..1012] consensus) (NN:[1013..1019] region))
                      (PP (IN:[1020..1022] of)
                        (NP (DT:[1023..1026] the) (NN:[1027..1039] beta-catenin)
                            (NN:[1040..1044] gene)))))))))))
      (PP (IN:[1045..1047] in)
        (NP (CD:[1048..1050] 43)
           (JJ:[1052..1059] gastric) (NNS:[1060..1067] cancers))))
    (.:[1067..1068] .)))

;sentence 8 Span:1069..1351
;All of these mutations were missense mutations, of which five  are in the
;highly conserved aspartic acid 32 and two are in serine 29; all of  these
;seven mutations were detected exclusively in intestinal-type gastric  cancers
;(7 of 26; 26.9%), but not in the diffuse-type (0 of 17).
;[1082..1091]:variation-event:"mutations"
;[1097..1115]:variation-type:"missense mutations"
;[1160..1173]:variation-state-original:"aspartic acid"
;[1174..1176]:variation-location:"32"
;[1192..1198]:variation-state-original:"serine"
;[1199..1201]:variation-location:"29"
;[1223..1232]:variation-event:"mutations"
;[1262..1294]:malignancy:"intestinal-type gastric  cancers"
;[1278..1294]...[1328..1340]:malignancy:"gastric  cancers"..."diffuse-type"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1069..1072] All))
        (PP (IN:[1073..1075] of)
          (NP (DT:[1076..1081] these) (NNS:[1082..1091] mutations))))
      (VP (VBD:[1092..1096] were)
        (NP-PRD
          (NP (JJ:[1097..1105] missense) (NNS:[1106..1115] mutations))
          (,:[1115..1116] ,)
          (SBAR
            (WHPP-1 (IN:[1117..1119] of)
              (WHNP (WDT:[1120..1125] which)))
            (S
              (S
                (NP-SBJ
                  (NP (CD:[1126..1130] five))
                  (PP-1 (-NONE-:[1130..1130] *T*)))
                (VP (VBP:[1132..1135] are)
                  (PP-PRD (IN:[1136..1138] in)
                    (NP (DT:[1139..1142] the)
                      (ADJP (RB:[1143..1149] highly)
                            (VBN:[1150..1159] conserved))
                      (NML (JJ:[1160..1168] aspartic) (NN:[1169..1173] acid))
                      (CD:[1174..1176] 32)))))
              (CC:[1177..1180] and)
              (S
                (NP-SBJ
                  (NP (CD:[1181..1184] two))
                  (PP-1 (-NONE-:[1184..1184] *T*)))
                (VP (VBP:[1185..1188] are)
                  (PP-PRD (IN:[1189..1191] in)
                    (NP (NN:[1192..1198] serine) (CD:[1199..1201] 29))))))))))
    (::[1201..1202] ;)
    (S
      (NP-SBJ-2
        (NP (DT:[1203..1206] all))
        (PP (IN:[1207..1209] of)
          (NP (DT:[1211..1216] these) (CD:[1217..1222] seven)
              (NNS:[1223..1232] mutations))))
      (VP (VBD:[1233..1237] were)
        (VP
          (VP (VBN:[1238..1246] detected)
            (NP-2 (-NONE-:[1246..1246] *))
            (ADVP=3 (RB:[1247..1258] exclusively))
            (PP-LOC=4 (IN:[1259..1261] in)
              (NP
                
                (NML (JJ:[1262..1272] intestinal) (HYPH:[1272..1273] -)
                     (NN:[1273..1277] type))
                (JJ:[1278..1285] gastric) (NNS:[1287..1294] cancers)
                (PRN (-LRB-:[1295..1296] -LRB-)
                  (FRAG
                    (NP
                      (NP (CD:[1296..1297] 7))
                      (PP (IN:[1298..1300] of)
                        (NP (CD:[1301..1303] 26))))
                    (::[1303..1304] ;)
                    (NP (CD:[1305..1309] 26.9) (NN:[1309..1310] %)))
                  (-RRB-:[1310..1311] -RRB-)))))
          (,:[1311..1312] ,) (CC:[1313..1316] but)
          (VP (RB:[1317..1320] not)
            (ADVP=3 (-NONE-:[1320..1320] *NOT*))
            (PP-LOC=4 (IN:[1321..1323] in)
              (NP (DT:[1324..1327] the) (JJ:[1328..1335] diffuse)
                  (HYPH:[1335..1336] -) (NN:[1336..1340] type)
                (PRN (-LRB-:[1341..1342] -LRB-)
                  (NP
                    (NP (CD:[1342..1343] 0))
                    (PP (IN:[1344..1346] of)
                      (NP (CD:[1347..1349] 17))))
                  (-RRB-:[1349..1350] -RRB-))))))))
    (.:[1350..1351] .)))

;sentence 9 Span:1352..1556
;We concluded  that disruption of the APC/beta-catenin/T cell factor-lymphoid
;enhancer binding  factor pathway might play an important role especially in
;the development of  intestinal-type gastric cancer.
;[1389..1392]:gene-generic:"APC"
;[1393..1405]:gene-generic:"beta-catenin"
;[1406..1419]:gene-protein:"T cell factor"
;[1420..1453]:gene-protein:"lymphoid enhancer binding  factor"
;[1525..1555]:malignancy:"intestinal-type gastric cancer"
(SENT
  (S
    (NP-SBJ (PRP:[1352..1354] We))
    (VP (VBD:[1355..1364] concluded)
      (SBAR (IN:[1366..1370] that)
        (S
          (NP-SBJ
            (NP (NN:[1371..1381] disruption))
            (PP (IN:[1382..1384] of)
              (NP (DT:[1385..1388] the)
                (NML
                  (NML (NN:[1389..1392] APC))
                  (SYM:[1392..1393] /)
                  (NML (NN:[1393..1405] beta-catenin))
                  (SYM:[1405..1406] /)
                  (NML (NN:[1406..1407] T) (NN:[1408..1412] cell)
                       (NN:[1413..1419] factor))
                  (HYPH:[1419..1420] -)
                  (NML
                    (NML (JJ:[1420..1428] lymphoid) (NN:[1429..1437] enhancer))
                    (VBG:[1438..1445] binding) (NN:[1447..1453] factor)))
                (NN:[1454..1461] pathway))))
          (VP (MD:[1462..1467] might)
            (VP (VB:[1468..1472] play)
              (NP (DT:[1473..1475] an) (JJ:[1476..1485] important)
                  (NN:[1486..1490] role))
              (PP
                (ADVP (RB:[1491..1501] especially))
                (IN:[1502..1504] in)
                (NP
                  (NP (DT:[1505..1508] the) (NN:[1509..1520] development))
                  (PP (IN:[1521..1523] of)
                    (NP
                      (NML (JJ:[1525..1535] intestinal) (HYPH:[1535..1536] -)
                           (NN:[1536..1540] type))
                      (JJ:[1541..1548] gastric) (NN:[1549..1555] cancer))))))))))
    (.:[1555..1556] .)))

;section 10 Span:1560..1605
;PMID: 10485468 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1560..1564] PMID) (::[1564..1565] :) (CD:[1566..1574] 10485468)
        (IN:[1575..1576] -LSB-) (NNP:[1576..1582] PubMed) (HYPH:[1583..1584] -)
        (JJ:[1585..1592] indexed) (IN:[1593..1596] for)
        (NNP:[1597..1605] MEDLINE-RSB-)))
